Scientists at Duke-NUS Medical School have uncovered why some pancreatic and colorectal cancers fail to respond to Wnt inhibitors, a promising new class of cancer drugs currently under development for these cancers. Their discovery, published in Science Advances, not only offers a new cancer therapy target but also a potential screening tool to identify those patients who will not benefit from this new therapy once it becomes available.
Comments are closed.